Skip to main content
Fig. 3 | Trials

Fig. 3

From: An Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study

Fig. 3

ILiAD drug administration chart with each provision of IMP, carers are provided with a drug administration chart. Each day, the carer crosses off the tablet on the chart as the IMP is given to the participant. Researchers review these charts at the end of each month to ensure concordance with IMP administration. The example above is for weeks 1 to 4 in the study

Back to article page

Trials

ISSN: 1745-6215